Multifactorial, site-specific recurrence model after radical cystectomy for urothelial carcinoma

Cancer

Volumn 116, Issue 14, 2010, Pages 3399-3407

  Umbreit, Eric C ^a   Crispen, Paul L ^a   Shimko, Mark S ^a   Farmer, Sara A ^a   Blute, Michael L ^a   Frank, Igor ^a  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

Cystectomy; Postoperative period; Recurrence; Transitional cell carcinoma

Indexed keywords

ABDOMINAL CANCER; ADULT; AGED; ALGORITHM; ARTICLE; BONE CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE FREE SURVIVAL; FEMALE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OBESITY; OCCUPATIONAL EXPOSURE; PELVIS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RADIATION EXPOSURE; RECURRENCE RISK; RISK FACTOR; SCORING SYSTEM; THORAX CANCER; URINARY TRACT CANCER; UROGENITAL TRACT TUMOR; UROTHELIAL CARCINOMA;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BONE NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PELVIC NEOPLASMS; POSTOPERATIVE PERIOD; RECURRENCE; RISK ASSESSMENT; THORACIC NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 77954891026     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25202     Document Type: Article

References (34)

1. Hassan JM, Cookson MS, Smith JA Jr, Chang SS. Patterns of initial transitional cell recurrence in patients after cystectomy. J Urol. 2006;175:2054-2057.
2. Ghoneim MA, El-Mekresh MM, El-Baz MA, El-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol. 1997;158:393-399. (Pubitemid 27327674)
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675. (Pubitemid 32120143)
4. Abe T, Shinohara N, Harabayashi T, et al. Impact of multi-modal treatment on survival in patients with metastatic urothelial cancer [see comment]. Eur Urol. 2007;52:1106-1113.
5. Cowles RS, Johnson DE, McMurtrey MJ. Long-term results following thoracotomy for metastatic bladder cancer. Urology. 1982;20:390-392.
6. Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998;159:792-795.
7. Lehmann J, Suttmann H, Albers P, et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009;55:1293-1299.
8. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol. 2001;165:811-814. (Pubitemid 32156284)
9. Sweeney P, Millikan R, Donat M, et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003;169:2113-2117.
10. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004;171:145-148.
11. Slaton JW, Swanson DA, Grossman HB, Dinney CP. A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1999;162(pt 1):710-714.
12. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
13. Montie JE. Follow-up after cystectomy for carcinoma of the bladder. Urol Clin North Am. 1994;21:639-643.
14. Sved PD, Gomez P, Nieder AM, Manoharan M, Kim SS, Soloway MS. Upper tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: incidence and risk factors. BJU Int. 2004;94:785-789.
15. Balaji KC, McGuire M, Grotas J, Grimaldi G, Russo P. Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation. J Urol. 1999;162:1603-1606.
16. Malkowicz SB, Skinner DG. Development of upper tract carcinoma after cystectomy for bladder carcinoma. Urology. 1990;36:20-22.
17. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
18. Volkmer BG, Kuefer R, Bartsch GC Jr, Gust K, Hautmann RE. Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol. 2009;181:1587-1593.
19. Holmäng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol. 1998;160:45-48.
20. Oosterlinck W, Lobel B, Jakse G, Malmström P-U, Stöckle M, Sternberg C. Guidelines on bladder cancer. Eur Urol. 2002;41:105-112.
21. Dhar NB, Jones JS, Reuther AM, et al. Presentation, location and overall survival of pelvic recurrence after radical cystectomy for transitional cell carcinoma of the bladder. BJU Int. 2008;101:969-972.
22. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
23. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
24. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
25. Suyama T, Ueda T, Fukasawa S, et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol. 2009;39:244-250.
26. Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer. 2008;113:1284-1293.
27. Peirce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res. 1996;146:1-27.
28. Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988;116:3-55.
29. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398-406.
30. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429-1439.
31. Sont WN, Zielinski JM, Ashmore JP, et al. First analysis of cancer incidence and occupational radiation exposure based on the National Dose Registry of Canada. Am J Epidemiol. 2001;153:309-318.
32. Sigurdson AJ, Doody MM, Rao RS, et al. Cancer incidence in the U.S. radiologic technologists health study, 1983-1998. Cancer. 2003;97:3080-3089.
33. Koebnick C, Michaud D, Moore SC, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2008;17:1214-1221.
34. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, height, physical activity and incidence of bladder cancer in US men and women. Int J Cancer. 2007;120:140-146.